FOXO's Risky Remedy: A Healthcare Pivot After NYSE Delisting

WEST PALM BEACH, FL – December 15, 2025 – In a bold declaration of reinvention, FOXO Technologies Inc. (OTC: FOXO) CEO Seamus Lagan has laid out a vision for a company reborn as a diversified healthcare operator. A year-end review detailed a flurry of acquisitions, a strengthened balance sheet, and impressive operational metrics from its new subsidiaries. However, this optimistic outlook is cast against the stark backdrop of the company's recent, humbling delisting from the NYSE American exchange, creating a high-stakes turnaround narrative that will test the limits of strategic pivots and investor confidence.

For a company whose stock was trading for fractions of a penny after a 99% price collapse, the message is clear: the past is the past, and the future is in healthcare. But for investors and analysts, the question is whether this aggressive M&A strategy is a sustainable cure for what ailed the company or merely a high-risk financial maneuver.

Forging a New Identity Through Acquisition

At the heart of FOXO's transformation is a rapid-fire acquisition spree that began in mid-2024, fundamentally reshaping the company into a healthcare holding entity. The strategy appears focused on acquiring operational assets in underserved or fragmented markets within Tennessee.

The most prominent success story is Myrtle Recovery Centers, a substance abuse treatment facility in Oneida. Since its acquisition, the center's performance has surged. According to the company, Myrtle is operating at 93% occupancy, with an average daily census of 28 patients, a dramatic increase from just 7.4 in 2024. Projected patient admissions are expected to triple to 550 in 2025. This high demand, which has the facility "consistently at capacity and having excess referrals," signals that FOXO has tapped into a critical community need, even securing funding from the State of Tennessee's Opioid Abatement Fund.

The company has also moved into acute care with the purchase of Rennova Community Health, which operates the Big South Fork Medical Center, a Critical Access Hospital. In a state where rural hospitals have faced one of the nation's highest closure rates, FOXO's investment provides a potential lifeline. The hospital is projected to handle over 7,000 emergency room visits and thousands of other patient encounters in 2025, underscoring its importance to the local healthcare infrastructure.

Most recently, FOXO ventured into the pharmaceutical services sector with the acquisition of Vector BioSource, a provider of biospecimens for research. While a smaller play, expected to generate around $1 million in 2025 revenue, it signals an ambition to build a third pillar in its healthcare portfolio, with Lagan noting "significant additional acquisition opportunities in this sector."

A Balance Sheet Under Reconstruction

Alongside the operational pivot, FOXO's management has been engaged in significant financial engineering. The company reports a vastly improved financial position, projecting annual revenues to exceed $15 million for 2025. More impressively, shareholder equity has reportedly quadrupled, climbing from $5.3 million at the end of 2024 to $20.2 million by September 30, 2025. During the same period, debt was reduced from $10.2 million to $7.1 million.

This cleanup involved settling legacy liabilities, such as a $2.3 million obligation to Smithline, and restructuring another $3.5 million in debt into preferred stock. These moves have uncluttered the balance sheet, presenting a healthier financial profile to potential investors and partners. However, the path to this improved state has not been without its own complications.

The Shadow of Delisting and Scrutiny

The optimistic operational and financial reports cannot entirely eclipse the serious challenges FOXO faces. In August 2025, the company's stock was delisted from the NYSE American after its share price fell below the exchange's minimum requirements, a direct consequence of a catastrophic price decline. The move relegated the stock to the less liquid and more speculative OTC markets.

Furthermore, investor confidence was tested when the company's board announced in August that its Q1 2025 financial statements should no longer be relied upon. The issue stemmed from a $5.1 million accounting error related to the purchase price of Rennova Community Health, requiring a future restatement. Such errors, even when corrected, can raise questions about a company's internal financial controls, particularly during a period of rapid M&A activity.

Leadership remains publicly undeterred. "We hope this can be achieved in 2026," Lagan stated regarding a potential uplisting back to a major exchange. However, the path back is arduous. It will likely require a significant reverse stock split to meet minimum price thresholds—a move already approved by stockholders—and a sustained period of flawless financial reporting and operational execution to convince regulators and the market that its turnaround is real.

A Creative Playbook for Growth

To fuel its acquisition strategy, FOXO has implemented a sophisticated financing structure centered on a new subsidiary, FOXO Acquisition Corporation (FAC), and a new class of Series E Cumulative Redeemable Secured Preferred Stock. This playbook is designed to enable growth while navigating the constraints of a microcap company with limited access to traditional capital markets.

The Series E Preferred Stock was used as currency in the Vector BioSource acquisition and is positioned as a key tool for future deals. The shares are secured by the equity of the acquisition subsidiary, FAC, offering a layer of protection to their holders. They are not convertible to common stock, a feature management highlights as "non-dilutive funding."

However, a closer look reveals a more nuanced picture for common shareholders. The Series E stock pays a 2.5% annual cash dividend and a 5% annual stock dividend in the form of common shares. While this structure conserves cash, the 5% stock dividend introduces a steady, creeping dilution for existing common stockholders over time. FOXO also intends to seek a separate public listing for this preferred series, which could create a new source of liquidity but also a distinct class of investors with different priorities and protections than common shareholders. This strategy is a calculated gamble that the value created by the acquisitions will far outweigh the future dilution from the financing used to secure them. The performance of these new assets and the leadership's ability to successfully integrate them will ultimately determine whether this financial engineering proves to be a masterstroke or a misstep.